Deciphera Pharmaceuticals

Deciphera Pharmaceuticals FCF Conversion

Delisted·Jun 10, 2024

The FCF Conversion Rate (FCF/EBITDA) of Deciphera Pharmaceuticals (DCPH) as of Oct 31, 2026 is 75.65 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 85.90 % — a change of -11.93% (lower).

FCF Conversion

75.65 %

YoY

-11.93%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Deciphera Pharmaceuticals is 2023 75.65 % . FCF Conversion Rate (FCF/EBITDA) of Deciphera Pharmaceuticals was 2022 85.90 % . It decreases by -11.93% lower compared to the previous year.

The Deciphera Pharmaceuticals FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
89.87 USD
Jan 1, 2017
73.80 USD
Jan 1, 2018
88.04 USD
Jan 1, 2019
80.54 USD
Jan 1, 2020
91.94 USD
Jan 1, 2021
83.14 USD
Jan 1, 2022
85.90 USD
Jan 1, 2023
75.65 USD
The Deciphera Pharmaceuticals FCF Conversion history
YEARFCF ConversionYoY
75.65 %-11.93%
85.90 %+3.32%
83.14 %-9.57%
91.94 %+14.15%
80.54 %-8.51%
88.04 %+19.30%
73.80 %-17.89%
89.87 %+32.80%
67.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Deciphera Pharmaceuticals Stock analysis

What does Deciphera Pharmaceuticals do? Deciphera Pharmaceuticals Inc is a US biopharmaceutical company specializing in the research, development, and marketing of innovative therapeutic solutions for cancer patients. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera follows a diversified business model based on multiple pillars. On one hand, the company conducts its own research and development activities to develop new therapy approaches for cancer patients. Deciphera focuses on the research of kinase inhibitors, which offer promising approaches in cancer therapy. On the other hand, the company pursues a licensing strategy by acquiring and further developing already developed active ingredients for cancer therapies in order to make them available to patients. For this purpose, the company collaborates with various partner companies and leading academics and experts in the field of cancer therapy. Deciphera is also engaged in international collaboration through partnerships with local partners in Asia for the research of new cancer therapy approaches. The company invests significant efforts in research and development to constantly adapt its products to the latest scientific advances. Deciphera aims to develop effective and safe therapies for cancer patients that improve their quality of life and increase their chances of survival. The company relies on the research of kinase inhibitors that specifically target certain signaling pathways in cancer cells and thereby inhibit the growth of tumor cells. The company already has a number of products in clinical trials and approval processes that show promising results and are expected to be on the market soon. One promising drug is Ripretinib, dedicated to the cancer type GIST. The goal is to offer a range of cancer medications that have significant treatment success and offer customers high chances of success. Overall, Deciphera Pharmaceuticals is a dynamic and research-oriented company that utilizes the most innovative technologies to give hope to cancer patients and improve the treatment of cancer diseases. With its broad portfolio of active ingredients and therapy approaches, its international presence, and its dedicated research and development, Deciphera Pharmaceuticals Inc. is at the forefront when it comes to innovative cancer treatment therapies. Deciphera Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Deciphera Pharmaceuticals stock

FCF Conversion Rate (FCF/EBITDA) of Deciphera Pharmaceuticals is 75.65 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of Deciphera Pharmaceuticals changed from 85.90 % to 75.65 %, representing a -11.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Deciphera Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Deciphera Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Deciphera Pharmaceuticals

All Key Metrics — Deciphera Pharmaceuticals